The asymmetric reduction of C=C bonds goes in hand with the creation of up to two chiral centers and is thus one of the most widely employed strategies for the synthesis of chiral compounds. Whereas cis hydrogenation using homogeneous catalysts based on (transition) metals has been developed to a high standard, [1] stereocomplementary trans reduction is still at the stage of development. [2,3] The biocatalytic equivalent of this reaction is catalyzed by enoate reductases [EC 1.3.1.x], [4,5] commonly denoted as the "old yellow enzyme" family.[6] These common enzymes act through transfer of a hydride ion, derived from a flavin cofactor (FMNH 2 ), onto the b-carbon atom of an a,bunsaturated carbonyl compound, while a proton, derived from the solvent, adds from the opposite side onto the acarbon atom. As a consequence of this mechanism, the hydrogenation occurs in a trans-specific fashion. The catalytic cycle is completed by the reduction of FMN at the expense of NAD(P)H, which is regenerated by an additional redox reaction (Scheme 1). Although the mode of action of these enzymes has been elucidated in great detail, their application in preparative-scale biotransformations has been hampered for several reasons: although the best-studied enzymes from this group, which were isolated from strictly anaerobic bacteria such as Proteus and Clostridium spp., [7] were shown to be highly stereoselective, the sensitivity of these proteins towards traces of molecular oxygen prevented their practical application. As a consequence, whole-cell biotransformations using aerobic microorganisms, most prominently bakers yeast, [8] dominated the field. Although the stereoselectivities achieved were often excellent, the chemoselectivity of wholecell bioreductions with respect to the reduction of C = C against C=O bonds was notoriously plagued by the competing reduction of the carbonyl group that was catalyzed by alcohol dehydrogenases. [9,10] Since enoate reductases and alcohol dehydrogenases depend on the same nicotinamide cofactor, redox decoupling of both enzyme activities is not possible.Isolated and/or cloned enoate reductases are required in sufficient amounts, together with a suitable recycling system for the nicotinamide cofactor, to make this biotransformation practically feasible. Only recently, the first successful attempts in the chemo-and stereoselective reduction of conjugated enones were reported by using cloned old yellow enzymes from Saccharomyces carlsbergensis [11] and bakers yeast. [12] Since enoate reductases have been shown to possess a much broader substrate spectrum than their name would suggest, [13] we initiated a search for a candidate that possessed a broad substrate specificity but showed high stereoselectivity towards a wide range of C = C bonds bearing an electronwithdrawing activating group. In this context, we came across 12-oxophytodienoate reductase (OPR) which occurs in several isoforms in plants. [14] Whereas isoenzyme OPR3 is responsible for the reduction of (9S,13S)-12-oxophytodienoate to the corre...